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Proteinase 3; a potential target in chronic
obstructive pulmonary disease and other
chronic inflammatory diseases
Helena Crisford1,3* , Elizabeth Sapey1 and Robert A. Stockley2
Abstract
Chronic Obstructive Pulmonary Disease (COPD) is a common, multifactorial lung disease which results in significant
impairment of patients’ health and a large impact on society and health care burden. It is believed to be the result
of prolonged, destructive neutrophilic inflammation which results in progressive damage to lung structures. During
this process, large quantities of neutrophil serine proteinases (NSPs) are released which initiate the damage and
contribute towards driving a persistent inflammatory state.
Neutrophil elastase has long been considered the key NSP involved in the pathophysiology of COPD. However, in
recent years, a significant role for Proteinase 3 (PR3) in disease development has emerged, both in COPD and other
chronic inflammatory conditions. Therefore, there is a need to investigate the importance of PR3 in disease
development and hence its potential as a therapeutic target. Research into PR3 has largely been confined to its role
as an autoantigen, but PR3 is involved in triggering inflammatory pathways, disrupting cellular signalling, degrading
key structural proteins, and pathogen response.
This review summarises what is presently known about PR3, explores its involvement particularly in the
development of COPD, and indicates areas requiring further investigation.
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Background
The serine proteinase Proteinase 3 (PR3) is an enzyme
released during neutrophilic inflammation and is capable
of cleaving many targets including key structural proteins
of the lung. Chronic Obstructive Pulmonary Disease
(COPD) is an inflammatory condition associated with
neutrophilic inflammation. For this reason neutrophil
elastase (NE) has long been considered to be a central,
proteinase in the pathophysiology as it can replicate many
of the structural changes of the disease and hence a poten-
tial target for therapeutic manipulation, PR3,another key
neutrophil serine proteinase has largely been ignored,
even though it may have an important additional role in
the lung as well as other human diseases [1]. This review
summarises the current literature to provide an update on
the potential role of PR3 in health and disease, with a
primary focus on COPD.
Proteinase 3
PR3, alternatively referred to as myeloblastin, azurophil
granule protein-7 or p29b, is a highly abundant neutro-
phil protein which is genetically transcribed in primitive
myeloid and monocytic progenitor cells, and expressed
in cells of granulocyte and monocyte linage, especially
neutrophils but including mast cells and basophils [2–5]
and in the neutrophil, it is mainly located within the
primary azurophil granules of the mature cell but is also
present in specific granules, secretory vesicles, and on
the cell surface [6, 7]. It is expressed constitutively on
the membrane by naïve neutrophils in peripheral blood
of healthy individuals (known as “constitutive” PR3) and
is secreted into extracellular medium by activated
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neutrophils following granule translocation to the cell
membrane (known as “induced” PR3) [8–11].
It is encoded by the gene PRTN3 which is located at hu-
man chromosome 19p13.3 and spans 6.57 kb pairs includ-
ing 5 exons and 4 introns. The gene consists of 222 amino
acids that fold to form the 29 kDa glycoprotein PR3 [4].
PR3 is classified within the family of “chymotrypsin”-
like neutrophil serine proteinase (NSP) which are identi-
fied by their highly conserved catalytic triads (His57,
Asp102 and Ser195; using chymotrypsinogen number-
ing) for proteolytic activity and defined by their active
site serine residue [4, 12]. PR3 possesses an enlarged
binding site with high specificity and differs from NE by 4
main subsites, S2, S1’, S2’ and S3’ (Fig. 1). which is com-
mon to other NSPs, including NE [12]. However, PR3,
specificity is further defined by difference in residues
which alter subsite specificities (subsites shown in Fig. 1).
These specificities are determined by:
 Amide hydrogens on Gly193 and Ser195 which
stabilise charge during catalysis [14].
 3 charged residues: Lys99, Asp61, Arg143 within the
active site region.
 Positioning of the solvent accessible Lys99
(compared to Leu99 in NE), which borders the S2
and S4 sites and makes the S2 subsite deeper and more
polar, in addition to reducing its hydrophobicity, which
determines preferential binding of negative and polar
residues, such as Asp [12, 16, 17].
 Asp61 brings the proteins negatively charged side
chain closer to the S1’ and S’3 subsites, making the
subsites smaller and more polar, which encourages
binding of basic residues at P1’ and P’3 [12, 16].
 Arg143 (and Pro151) increase the polarity of the S2’
subsite which creates a basic S2’ subsite that binds
acidic residues [12, 16].
 Asp213 (compared to Ala213 in NE) restricts the S1
binding site causing it to preferably bind small
hydrophobic residues at P1, which includes alanine,
serine, valine, norvaline, and methionine [12, 14, 16–18].
 Ile217 allows small hydrophobic residues at P4 to
bind whilst with Trp218 creating a more
hydrophobic S5 subsite [12, 14, 16].
PR3 is initially transcribed as an inactive precursor re-
ferred to as a zymogen and then undergoes a two-stage
posttranslational modification to become active. Firstly
(via signal peptidase), there is N-terminal signal peptide
cleavage, followed by cleavage of the N-terminal pro-di-
peptide by the cysteine proteinase, cathepsin C which is
essential for enzymatic activity. Secondly it undergoes
pro-peptide cleavage at the C terminal, which is crucial
for granule packaging. This forms the catalytic triad of
residues and the final conformation of mature PR3, as
shown in Fig. 2, which is stabilised by disulphide bonds
and appropriate asparagine-linked glycosylation [4, 12,
20]. PR3 then remains stored within the neutrophil azur-
ophil granules until release.
There is estimated to be 3 pg of PR3 stored in each
neutrophil, alongside other key serine proteinases, with a
mean PR3 concentration of 13.4 mM in each granule,
which is 3–4 fold higher than NE [23]. Once released, ei-
ther constitutively or via granule translocation, PR3 can
act enzymatically in both an intracellular and extracellular
manner. Its activity is then controlled through inactivation
by inhibitors (both reversibly and irreversibly), including
serine proteinase inhibitors (Serpins), chelonianin inhibi-
tors and also alpha-2-macroglobulin [24–26].
PR3 has many functions. Animal transgenic and knock-
out models have demonstrated that it is able to cleave
structural proteins leading to tissue remodelling (as
discussed within ‘Pathophysiological functions of PR3 in
COPD’), through diffusing deeper into tissues than the
other NSPs [27–30]. Other functions assist in the defen-
sive immune role of the neutrophil including regulating a
variety of cellular processes, cleaving host protein into
Fig. 1 Diagrammatically demonstrates the substrate binding pockets S4-S3’ of PR3 with substrate cleavage positions P4-P3’, according to the
Schechter and Berger enzyme-ligand binding site numbering convention [19]. The arrows indicate the sites for Val/Ala-containing peptide
cleavage and hydrophobic residue binding sites, whilst + indicates positive and – indicates negative residue binding site. Adapted from [13]
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antibacterial peptides and activating pro-inflammatory
cytokines [31, 32]. Dysfunction of these systems has long
been associated with the development or progression of a
number of chronic inflammatory diseases including COPD,
but often without reference to the potential role of PR3.
Pathophysiological functions of proteinase 3 in
COPD
PR3 is likely to have more involvement in the patho-
physiology of COPD than previously thought, supported
by evidence of increased PR3 activity described in these
patients [33–35]. COPD is a progressive, destructive
lung disease associated with chronic neutrophilic inflam-
mation and marked by obstruction of airflow, reduced
physical activity and breathlessness [36].
The pathophysiology of COPD is considered to reflect
an imbalance between proteinases and anti-proteinases
in the lung, and Sinden et al. produced the first substan-
tive evidence to support the role of PR3 in a three-di-
mensional reaction diffusion lung interstitium model
[27]. The authors demonstrated that active proteinase
diffusion distance following release from a neutrophil
varies predominantly depending on concentrations of
local physiological inhibitors and that this was greater
for PR3 than NE [27]. Generally, activated proteinases
have the potential to cause direct lung damage, whereas
anti-proteinases provide protection to limit this process.
In the lungs, a homeostatic balance is largely maintained,
with the exception of a region of quantum proteolysis
surrounding migrating and degranulating neutrophils
which is larger in patients with α-1 anti-trypsin deficiency
(AATD) explaining the increased susceptibility of these
subjects to COPD [37]. This reflects the high concentra-
tions of NSPs released from the granules compared to the
immediate concentration of the physiological inhibitors.
As the NSPs diffuse away from the neutrophil, the
concentration falls exponentially until it equals that of the
surrounding inhibitors when activity ceases [37]. It is
believed that when levels of NSPs, including PR3, exceed
the amount of protective anti-proteinases, such as α-1
anti-trypsin (AAT), excessive damage to lung tissue and
other proteinase effects are facilitated [38].
It was previously believed that NE played the key neu-
trophilic role in tissue damage leading to emphysema,
especially in subjects with genetic deficiency of AAT.
However, recent data has challenged this concept and
supports a potential role for other NSPs including PR3
[33]. Firstly, when a migrating neutrophil degranulates
in vitro, it is expected to release more PR3 than NE from
the azurophil granules. In vitro some of this becomes
membrane bound and more resistant to inhibition, also
the free enzyme still has a far greater radius of activity
than NE [10, 39, 40]. In addition, although local
lung-derived inhibitors are able to inhibit NE the same
is not true for PR3, and persistent activity is detectable
in lung secretions when NE activity is not [41, 42]. This
is important as it implies all the pathological changes in
the lung attributed to NE may also be produced by PR3
and potentially to a greater extent.
This theory is supported in vivo by the development of
emphysema in hamsters receiving local administration
of PR3 and further by recent evidence that SerpinA1-de-
ficient murine models develop spontaneous emphysema
[43, 44]. In addition, NSP-knockout murine models are
protected against developing emphysema induced by
cigarette smoke, whereas mice only deficient in NE are
less susceptible, implying that either cathepsin G or PR3
played an important role [30]. Collectively these models
suggest that, as well as NE, PR3 is potentially able to
contribute to the development of emphysema in
humans.
Biochemical studies have shown that PR3 cleaves
extracellular matrix (ECM) proteins, including elastin,
fibronectin, vitronectin, laminin and collagen, at a
GXXPG site within a β-fold conformation resulting in
protein degradation [17, 45, 46]. These proteins are
important components of tissue structures and, it is the
degradation of the extracellular matrix which results in
the connective tissue injury in the lung interstitium
leading to emphysema, as observed using biomarkers in
human COPD and as induced in several animal models
[43, 46–48]. Indeed, recent evidence suggests PR3 spe-
cific cleavage of elastin is elevated in COPD providing
more direct evidence of its role [33].Like other NSPs,
Fig. 2 Three-dimensional visualisation of Proteinase 3 by ribbon plot,
with the catalytic triad and PR3-specific residues stylised in a stick
representation and annotated. Image developed from the Proteinase 3
Protein Data Bank entry (PDB ID: 1FUJ) [15, 21] using YASARA [22]
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PR3 can also affect mucus clearance by damaging bron-
chial epithelium and cilia [16]. In addition, PR3 is able
to induce mucus production from submucosal gland
serous cells and PR3 activity has been implicated in this
role in cystic fibrosis (CF) [49]. The net result is excess
mucus production in the airways and impaired mucus
clearance, which is also a feature of chronic bronchitis,
and therefore PR3 is likely to have a similar role in
COPD. AATD is a genetic cause of emphysema and
chronic bronchitis (in about 30% of patients) and is the
result of mutations resulting in little/no production of
functional AAT protein. PR3 has a lower association rate
with AAT than NE, which means that, in patients with
AATD, PR3 is even more poorly regulated, causing a
greater proteinase/anti-proteinase imbalance than with
NE, and hence potentially mediates more damage to the
lungs [4, 27, 50].
As well as causing direct tissue damage, PR3 is also
potentially involved in amplifying the inflammation
associated with COPD as with other chronic inflamma-
tory diseases.
PR3 is known to modulate a variety of cytokine
functions, which impact processes such as metabolism
and inflammasome generation [51–53]. The enzyme
facilitates an increased production and/or modulation
of proinflammatory cytokines and the reduction of
anti-inflammatory cytokine production as summarised
in Table 1. Many of these cytokines have been impli-
cated in a number of inflammatory diseases, which
supports a putative role of PR3 in chronic inflamma-
tory conditions in general as well as COPD with and
without AATD.
All these cytokines can act through autocrine, para-
crine and endocrine pathways to activate
pro-inflammatory cascade responses and upregulate
pro-inflammatory genes and transcription factors leading
to an inflammatory state [65]. The products of these key
inflammatory pathways can further induce feedback
loops to enhance chronic inflammation [66–68]. There-
fore (similarly to NE) PR3 can potentially play multiple
roles in the initiation and amplification as well as the
resolution of inflammation, at least as demonstrated in
vitro.
More recently, PR3 has been also found to degrade
the anti-inflammatory mediator progranulin (PGRN),
resulting in generation of granulin (GRN) peptides in
vitro [32, 68–70]. PGRN degradation causes increased
neutrophil infiltration, activation of reactive oxidative spe-
cies, pro-inflammatory cytokine production and
anti-inflammatory pathway inhibition, sustaining an
inflammatory state in other inflammatory disease [71].
GRN molecules are also known to accumulate and release
the chemoattractant interleukin (IL)-8 amplifying neutro-
phil recruitment [70, 72]. In clinically-stable COPD, the
concentration of PR3 in airway secretions is a stronger
predictor of PGRN levels than NE, because of its greater
neutrophil concentration and hence greater secretion
activity [69].
PR3 is also able to act in a pro-inflammatory manner by
interacting with the complement pathway. It is able to
fragment the neutrophil surface complement component
5a (C5a) receptor, resulting in the loss of the N-terminus
and an inability to bind C5a [73]. In CF, the lack of C5aR
signalling contributes towards inefficient clearance of mi-
crobial infections in vitro and also inactivates signalling
and stimulates neutrophils to degranulate [73]. This
results in a cycle of dysfunctional neutrophils thereby
perpetuating the bacterial-stimulated inflammatory signals
and further neutrophil recruitment. Although there is no
direct evidence, it is likely that C5aR inhibition by PR3
also has a role in COPD with elevated levels of C5a in the
sputum of patients and correlations with circulating C5a,
physiological gas transfer and the degree of emphysema
[74]. Further research is clearly indicated to determine the
relevance of this mechanism in COPD.
Despite the potential to impede bacterial clearance,
it has also been reported that PR3 itself possesses
bactericidal properties through cleavage of the pro-
microbicidal protein hCAP-18 (human cathelicidin)
into the antibacterial peptide, mucus inducer and neu-
trophil chemo-attractant LL-37 [51, 75–78]. Furthermore,
levels of LL-37 in sputum are related to disease severity in
patients with COPD suggesting an indirect role for PR3
which is worthy of further investigation [79].
In addition, PR3 can adhere to neutrophil extracellular
traps (NETs) contributing towards the destruction of
bacterial virulence factors [80–82]. However, many
respiratory-relevant bacteria, such as Streptococcus
pneumoniae and Haemophilus influenzae, have evolved
NET evasion mechanisms which may overcome this
potential clearance mechanism [83, 84]. It has also been
noted that patients with Pseudomonas aeruginosa infec-
tion are more susceptible to poor outcome when lacking
sufficient PR3 inhibition and patients with AATD are at
particularly high risk of respiratory infection and lung
damage as other natural proteinase inhibitors are unable
to compensate for low AAT levels [27, 85]. This is again
amplified by the greater neutrophil PR3 content and the
fact that the other major lung inhibitor of serine protein-
ases, secretory leukocyte proteinase inhibitor (SLPI), does
not inhibit PR3 [86].
However, PR3 is also able to inactivate SLPI, by cleaving
at the Ala-16 site within the N-terminal and preventing
SLPI/enzymes complex formation which would indirectly
amplify the local activity of other serine proteinases such
as NE [86].
Analysis of biopsied lung tissue, from patients with
severe emphysema, has shown that cytosolic PR3
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interrupts the initiation of anti-inflammatory mecha-
nisms and promotes an apoptotic environment, inducing
death of lung epithelial cells which has been implicated
in the pathophysiology of emphysema by a further indir-
ect route [87].
An additional mechanism implicated in the pathophysi-
ology of COPD involves the receptor for advanced glycation
end-products (RAGE) and soluble RAGE. In prostate cancer
cell lines, PR3 has been shown to bind to RAGE both pro-
moting cell activation and preventing its cleavage which es-
calates inflammation [88, 89]. Furthermore, decreased levels
of sRAGE have been implicated in emphysema development
[89, 90]. Clearly the relevance of this alternative function
also needs to be explored in relation to COPD.
Pathophysiological functions of proteinase 3 in
other diseases
The actions discussed above are not just relevant to
COPD but are relevant to the pathophysiology of many
other diseases. PR3 also has many additional roles which
can lead to, or amplify other disease states (see Fig. 3).
As noted in Table 1, PR3 has both a direct and indirect
effect on many cytokines and hence can have further
downstream influences on diseases beyond or associated
with COPD, as outlined in Table 2.
However, although the effects of dysregulation of these
cytokines are also implicated in other diseases, PR3 has
not been directly studied in relation to their
pathophysiology.
In addition, the interaction between PR3 and PGRN
also likely has wider impact than in COPD, through a
further role in inflammatory conditions involving PGRN,
including lipopolysaccharide-induced acute lung injury,
dermatitis and inflammatory arthritis (in murine
models), as well as a reported genetic link between
loss-of-function mutations in PGRN and the develop-
ment of neurodegenerative disease [99–104].
It is also suspected that PR3, alongside other NSPs,
could have a role in ECM breakdown affecting the
pathophysiology of diseases in other organs, such as
aneurysms due to vascular remodelling as shown in
porcine vasculature; however the relevance has not yet
been investigated in detail in humans [105].
PR3 has a role in the efficacy of neutrophil transmigration
through interaction with the cell surface receptor NB1
(CD177) which acts with PECAM-1 (CD31) during
trans-endothelial migration of neutrophils [106, 107]. In CF,
this is supported by a positive relationship between PR3
activity and neutrophil migration effectiveness [20]. The
interaction of PR3 with NB1 and PECAM-1 is confirmed in
vitro in endothelial cells, where it inhibits activation and
upregulation of these adhesion molecules [108].
There is also evidence that PR3 is associated with distor-
tion of cellular signalling pathways and the development of
Fig. 3 Summary of the actions of Proteinase 3 (PR3), as outlined in this review, which likely impact on COPD and other systemic diseases. The
processes with a putative central role in the pathophysiology of emphysema are highlighted in bold
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autonomous cell growth. In leukaemia, early expression of
PR3 during haematopoiesis is able to induce factor-inde-
pendent growth and overexpression of PR3 in myeloid leu-
kaemia cells prevents their differentiation into monocytoid
cells supporting this mechanism [109–111].
Alternatively to its pro-apoptotic role in COPD, PR3
may paradoxically prevent apoptosis in granulomatosis
with polyangiitis (GPA) by associating with calreticulin,
through co-externalisation with phosphatidylserine by
phospholipid flip-flop via phospholipid scramblase 1
(PLSCR1), to override the ‘eat me’ signalling [112].
Finally, PR3 also has a role as an autoantigen in
many diseases, including GPA and idiopathic interstitial
pneumonias, and is the target of cytoplasmic (c)-anti-
neutrophil cytoplasmic antibodies, also referred to as
PR3-ANCA in vasculitis [113–115]. Development of
disease is dependent on ability of PR3 to associate with
the cell membrane [112]. The binding of PR3-ANCA
with cell associated PR3 initiates a cascade which
amplifies inflammation and results in local cellular and
tissue damage [9, 114, 116–118].
It was suspected that PR3-ANCA formation may have a
role in COPD development, as more patients with COPD
were found to be antinuclear antibody positive than healthy
controls [119]. However, despite a reported association
with emphysema-dominant disease and lower body mass
index, no clear pathophysiological relationship has been
established [119]. These wide ranging pro-inflammatory
effects of PR3 in other conditions therefore may be also
relevant in the pathophysiology of COPD, both directly by
tissue damage and indirectly through other multiple path-
ways of inflammation.
Table 1 Summary of the cytokines affected by PR3, with the PR3 action on cytokines and the resulting response. The processes
relevant to the pathophysiology of COPD are highlighted in bold
Cytokine Role of PR3 Action of cytokine References
Interleukin
(IL)-1β
Proteolytically activates extracellular pro-forms
to be cleaved into active counterparts by
Caspase 1 in inflammasomes
• ↑ neutrophil activation and recruitment
• canonical NFκB signalling
• ↑ cyclooxygenases [44] and prostaglandin
E production
• pushes towards T helper cell (Th)17 differentiation
[31, 54–56]
IL-18 • Induces interferon (IFN)-γ and Fas ligand, ↑ differentiation
to Th1, Th2 or Th17 responses
(dependant on accompanying signals)
[55, 57]
Tumour necrosis
factor (TNF)-α
Cleaves precursor to bioactive form (via two
hypothesised cleavage sites at Ala15-Leu16
or Val77-Arg78)
• Activates the caspase and MEK cascades,
and PI-3-kinase and canonical NFκB pathway
• Activates Etk = ↑cellular adhesion, migration
and propagation
• ↑ neutrophil chemotaxis
• Upregulation of pro-inflammatory genes e.g.
IL-8, CCL2, CXCL10, COX-2, and pro-coagulants
• Recruits apoptosis-inhibiting molecules
• ↓ signalling by cIAP-mediated ubiquitination
[54, 58]
IL-6 Functionally inactivates and degrades the
soluble IL-6 receptor (sIL-6R) – exact
mechanisms unknown
• Disrupts trans-signalling activity
• Prevents apoptosis
• ↑ neutrophil recruitment and infiltration
[59, 60]
IL-8 (CXCL8) Truncates stored IL-8 (77) into the 10-fold more
potent chemo-attractant IL-8 (70) through
cleavage of an Ala-Lys bond
• ↑ respiratory burst
• Potentiates inflammatory disease cycle
• Drives neutrophil chemotaxis
[61]
IL-17 (CTLA8) Stimulation increases cytokine production • Directs towards a dominant Th17 environment
• T cell hypo-responsiveness
[62]
IL-32 Processes activating cytokines IL-1β, TNF-α
and IFN-γ directly or indirectly; cleaves IL-32
at IL-32α to a more bioactive form
• Activates canonical NFκB and MAPK cascades
• ↑ production of cytokines incl. TNF-α, IL-8
and CXCL2 production
[63, 64]
Table 2 Cytokines influenced by PR3 (as shown in Table 1) and
implicated in disease states other than COPD
Cytokine Diseases Implicated References
Interleukin (IL)-1β • Rheumatoid arthritis
• Asthma
[91, 92]
IL-18 • Non-alcoholic fatty liver disease
• Type 2 diabetes
• Asthma
• Rheumatoid arthritis
[92–94]
Tumour necrosis
factor (TNF)-α
• Rheumatoid arthritis
• Interstitial Lung Disease
• Asthma
[95, 96]
IL-6 • Cystic fibrosis [97]
IL-17 (CTLA8) • Granulomatosis with polyangiitis [62]
IL-32 • Psoriasis
• Rheumatoid arthritis
• Crohn’s disease
[98]
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PR3 as a therapeutic target in COPD
There is considerable theoretical evidence and cell-based
and animal-model data to support the role of PR3 in the
development of COPD. However, as yet, PR3 activity in
COPD has been poorly characterised.
To study PR3 in COPD requires the ability to quantify
active (uninhibited) PR3 accurately and distinguish it
from other NSPs to determine its specific function
within biological samples. Reagents for free PR3 activity
have only lately become available and until recently,
detection required immunofluorescent staining of biopsy
specimens, which if positive was followed by a
PR3-ANCA specific enzyme-linked immunosorbent
assay (ELISA) [120, 121]. Indeed, this was the inter-
nationally accepted method for diagnosing PR3-ANCA.
Direct PR3 assays have been proposed as a biomarker to
determine PR3 presence and production for assisting a
diagnosis [122, 123]; however, like immunofluorescence
techniques, they do not distinguish the active PR3 from
PR3 which has been inactivated by its inhibitors. A
similar challenge was seen for the measurement of NE
activity and a novel approach to this has been the devel-
opment of NE specific footprint, which may also be a
more relevant approach for PR3 activity in vivo [124].
Whilst there is increasing interest in modifying NSP
activity in conditions which predominantly feature
neutrophilic inflammation, these have primarily focused
on reducing the activity of NE and PR3 has not generally
been considered as a relevant target in COPD.
The detection of PR3 activity, directly or indirectly,
would improve our understanding of its role in COPD
and individual patient’s disease activity. It would also
potentially allow earlier diagnosis of diseases where PR3
activity was relevant (including COPD) before extensive
damage has occurred. Understanding the role of PR3,
might therefore allow earlier interventions and thera-
peutic strategies to be developed with PR3 as a valid tar-
get in COPD. Specific inhibitors might serve to reduce
disease severity, mortality and the long-term health
burdens of COPD. However, clearly the limited data
available indicates there is much work to be done to
clarify the likely relevance and hence impact of an
anti-PR3 strategy.
Conclusions
PR3 has many important functions that are relevant to
human physiology and PR3 dysfunction may play a crit-
ical role in many processes central to the pathophysi-
ology of COPD and other chronic neutrophilic human
diseases. PR3 is the most abundant serine proteinase in
the neutrophil, secondarily inhibited to NE, and, in
addition to the role in general inflammation, PR3 can
also cause direct tissue damage central to structural
aspects of diseases such as COPD. This is consistent
with the potential for PR3 to produce all the patho-
logical changes of COPD that have traditionally been
attributed to NE. Understanding this role and the
impact on the inflammatory cascade has major implica-
tions for the design of anti-proteinase molecules aimed at
restoring proteinase/anti-proteinase balance, ensuring that
destructive activity of relevant serine proteinase action
and amplification of inflammation is effectively limited,
and thereby preventing the development and progression
of COPD.
Abbreviations
AAT: α-1 Anti-trypsin; AATD: α-1 Anti-trypsin Deficiency; ANCA: Anti-
neutrophil Cytoplasmic Antibodies; C5a: Complement Component 5a;
CF: Cystic Fibrosis; COPD: Chronic Obstructive Pulmonary Disease;
COX: Cyclooxygenases; DLCo: Diffusing Capacity of the Lungs for Carbon
Monoxide; ECM: Extracellular Matrix; ELISA: Enzyme-linked Immunosorbent
Assay; GPA: Granulomatosis with Polyangiitis; GRN: Granulin; hCAP-
18: Human Cathelicidin; IFN: Interferon; IL: Interleukin; NE: Neutrophil Elastase;
NETs: Neutrophil Extracellular Traps; NFkB: Nuclear Factor Kappa-Light-Chain-
Enhancer of Activated B Cells; NSP: Neutrophil Serine Proteinase;
PGRN: Progranulin; PLSCR1: Phospholipid Scramblase 1; PR3: Proteinase 3;
RAGE: Receptor for Advanced Glycation End-products; Serpins: Serine
Proteinase Inhibitors; SPLI: Secretory Leukocyte Proteinase Inhibitor; Th: T
helper Cells; TNF: Tumour Necrosis Factor
Authors’ contributions
All authors met criteria for authorship. HC wrote the initial draft of the
manuscript and, ES and RAS revised the manuscript. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
Not Applicable.
Consent for publication
Not Applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Institute of Inflammation and Ageing, University of Birmingham, Edgbaston,
Birmingham B15 2GW, UK. 2University Hospital Birmingham NHS Foundation
Trust, Edgbaston, Birmingham B15 2GW, UK. 3Institute of Inflammation and
Ageing, College of Medical and Dental Sciences, Centre for Translational
Inflammation Research, University of Birmingham Research Laboratories,
Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham B15
2WB, UK.
Received: 20 April 2018 Accepted: 6 September 2018
References
1. GOLD: Global strategy for the diagnosis, management and prevention of
chronic obstructive pulmonary disease. 2017.
2. Baici A, Szedlacsek SE, Fruh H, Michel BA. pH-dependent hysteretic behavior
of human Myeloblastin (leucocyte proteinase 3). Biochem J. 1996;317:901–5.
3. Karatepe K, Luo HR. Proteinase 3 is expressed in stem cells and regulates
bone marrow hematopoiesis. Blood. 2015;126:1159.
4. Korkmaz B, Moreau T, Gauthier F. Neutrophil elastase, proteinase 3 and
Cathepsin G: physiochemical properties, activity and Physiopathologcal
functions. Biochemie. 2008;90:227–42.
5. Zimmer M, Medcalf RL, Fink TM, Mattmann C, Lichter P, Jenne DE. Three
human elastase-like genes Coordingately expressed in the Myelomonocyte
Crisford et al. Respiratory Research  (2018) 19:180 Page 7 of 10
lineage are organised as a single genetic locus on 19pter. Proc Natl Acad
Sci U S A. 1992;89:5.
6. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils
express proteinase 3 on their plasma membrane In vitro and In vivo. Clin
Exp Immunol. 1994;95:244–50.
7. Witko-Sarsat V, Cramer EM, Hieblot C, Guichard J, Nusbaum P, Lopez S,
Lesavre P, Halbwachs-Mecarelli L. Presence of proteinase 3 in secretory
vesicles: evidence of a novel, highly Mobilizable intracellular Pool distinct
from Azurophil granules. Blood. 1999;94:2487–96.
8. Halbwachs-Mecarelli L, Bessou G, Lesavre P, Lopez S, Witko-Sarsat V.
Bimodal Distrubution of proteinase 3 (PR3) surface expression reflects a
constitutive heterogeneity in the Polymorphonuclear neutrophil Pool. FEBS
Lett. 1995;374:29–33.
9. Csernok E, Ludemann J, Gross WL, Bainton DF. Ultrastructural localisation of
proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in
Wegener's granulomatosis. Am J Pathol. 1990;137:1113–20.
10. Korkmaz B, Jaillet J, Jourdan M-L, Gauthier A, Gauthier F, Attucci S.
Catalytic activity and inhibition of Wegener antigen proteinase 3 on the
cell surface of human Polymorphonuclear neutrophils. J Biol Chem.
2009;284:19896–902.
11. Korkmaz B, Lesner A, Letast S, Mahdi YK, Jourdan ML, Dallet-Choisy S,
Marchand-Adam S, Kellenberger C, Viaud-Massuard MC, Jenne DE, Gauthier
F. Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as
pharmacological targets in granulomatosis with polyangiitis (Wegener
granulomatosis). Semin Immunopathol. 2013;35:411–21.
12. Hajjar E, Broemstrup T, Kantari C, Witko-Sarsat V, Reuter N. Structures of
human proteinase 3 and neutrophil elastase - so similar yet so different.
FEBS J. 2010;277:2238–54.
13. Hajjar E, Korkmaz B, Gauthier F, Brandsdal BO, Witko-Sarsat V, Reuter N.
Inspection of the binding sites of proteinase 3 for the Design of a Highly
Specific Substrate. J Med Chem. 2006;49:1248–60.
14. Guarino C, Gruba N, Grzywa R, Dyguda-Kazimierowicz E, Hamon Y,
Legowska M, Skorenski M, Dallet-Choisy S, Marchand-Adam S,
Kellenberger C, et al. Exploiting the S4-S5 specificity of human
neutrophil proteinase 3 to improve the potency of peptidyl
Di(chlorophenyl)-phosphonate Ester inhibitors: a kinetic and molecular
modeling analysis. J Med Chem. 2018;61:1858–70.
15. Fujinaga M, Chernaia MM, Halenbeck R, Koths K, James MNG. The crystal
structure of PR3, a neutrophil serine proteinase antigen of Wegener's
granulomatosis antibodies. J Mol Biol. 1996;261:267–77.
16. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase,
proteinase 3, and Cathepsin G as therapeutic targets in human diseases.
Pharmacol Rev. 2010;62:726–59.
17. Rao NV, Wehner NG, Marshall BC, Gray WR, Gray BH, Hoidal JR.
Characterisation of proteinase 3 (PR-3), a neutrophil serine proteinase:
structural and functional properties. J Biol Chem. 1991;266:9540–8.
18. Brubaker MJ, Groutas WC, Hoidal JR, Rao NV. Human neutrophil proteinase
3: mapping of the substrate binding site using peptidyl Thiobenzyl esters.
Biochem Biophys Res Commun. 1992;188:1318–24.
19. Schechter I, Berger A. On the size of the active site in proteases. I. Papain.
Biochem Biophys Res Commun. 1967;27:157–62.
20. Twigg MS, Brockbank S, Lowry P, FitzGerald SP, Taggart C, Weldon S. The
role of serine proteases and Antiproteases in the cystic fibrosis lung. Mediat
Inflamm. 2015;2015:10.
21. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN,
Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000;28:235–42.
22. Krieger E, Vriend G. YASARA view - molecular graphics for all devices - from
smartphones to workstations. Bioinformatics. 2014;30:2981–2.
23. Campbell EJ, Campbell MA, Owen CA. Bioactive proteinase 3 on the cell
surface of human neutrophils: quantification, catalytic activity, and
susceptibility to inhibition. J Immunol. 2000;165:3366–74.
24. Loison F, Xu Y, Luo HR. Proteinase 3 and serpin B1: a novel pathway in the
regulation of Caspase-3 activation, neutrophil spontaneous apoptosis, and
inflammation. Inflamm Cell Signal. 2014;1:1–5.
25. Zani ML, Nobar SM, Lacour SA, Lemoine S, Boudier C, Bieth JG, Moreau
T. Kinetics of the inhibition of Neutriophil proteinases by recombinant
Elafin and pre-elafin (Trappin-2) expressed in Pichia pastoris. Eur J
Biochem. 2004;271:2370–8.
26. Yang L, Mei Y, Fang Q, Wang J, Yan Z, DSong Q, Lin Z, Ye G. Identification
and characterization of serine protease inhibitors in a parasitic wasp,
Pteromalus puparum. Sci Rep. 2017;7:1-13.
27. Sinden NJ, Baker MJ, Smith DJ, Kreft J-U, Dafforn TR, Stockley RA.
Alpha-1-antitrypsin variants and the proteinase/anti-proteinase
imbalance in chronic obstructive pulmonary disease. Am J Physiol Lung
Cell Mol Physiol. 2015;308:12.
28. Jerke U, Perez Hernandez D, Beaudette P, Korkmaz B, Dittmar G, Kettritz R.
Neutrophil Serine Proteases Exert Proteolytic Activity on Endothelial Cells.
Kidney Int. 2015;88:764–75.
29. Korkmaz B, Lesner A, Guarino C, Wysocka M, Kellenberger C, Watier H,
Specks U, Gauthier F, Jenne DE. Inhibitors and antibody fragments as
potential anti-inflammatory therapeutics Targetting neutrophil proteinase 3
in human disease. Pharmacol Rev. 2016;68:603–30.
30. Guyot N, Wartelle J, Malleret L, Todorov AA, Devouassoux G, Pacheco Y,
Jenne DE, Belaaouaj A. Unopposed Cathepsin G, neutrophil elastase, and
proteinase 3 cause severe lung damage and emphysema. Am J Pathol.
2014;184:2197–210.
31. Joosten LA, Netea MG, Fantuzzi G, Koenders MI, Helsen MM, Sparrer H,
Pham CT, van der Meer JW, Dinarello CA, van den Berg WB. Inflammatory
Arthritis in Caspase 1 Gene-deficient Mice: Contribution of Proteinase 3 to
Caspase 1-independent Production of Bioactive Interleukin-1beta. Arthritis
Rheum. 2009;60:3651–62.
32. Kessenbrock K, Frohlich L, Sixt M, Lammermann T, Pfister H, Bateman A,
Belaaouaj A, Ring J, Ollert M, Fassler R, Jenne DE. Proteinase 3 and
neutrophil elastase enhance inflammation in mice by inactivating anti-
inflammatory Progranulin. J Clin Invest. 2008;118:2438–47.
33. Gudmann NS, Manon-Jensen T, Sand JMB, Diefenbach C, Sun S, Danielsen
A, Karsdal MA, Leeming DJ. Lung tissue destruction by proteinase 3 and
Cathepsin G mediated elastin degradation is elevated in chronic obstructive
pulmonary disease. Biochem Biophys Res Commun. 2018;503(3):1284-90.
34. Newby PR, Carter RI, Stockley RA. Aα-Val541 a Novel Biomarker of Proteinase
3 Activity. Am J Respir Crit Care Med. 2017;195:A5247.
35. Newby PR, Stockley RA. Neutrophil elastase and proteinase 3 activity in PiSZ
Alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2018;197:A4763.
36. Hoenderdos K, Condliffe A. The neutrophil in chronic obstructive pulmonary
disease. Too little, too late or too much, too soon? Am J Respir Cell Mol
Biol. 2013;48:531–9.
37. Campbell EJ, Campbell MA, Boukedes SS, Owen CA. Quantum proteolysis
by neutrophils: implications for pulmonary emphysema in α1-antitrypsin
deficiency. CHEST. 2000;117:303S.
38. Stockley RA. Neutrophils and protease/Antiprotease imbalance. Am J Respir
Crit Care Med. 1999;160:S49–52.
39. Owen CA, Campbell EJ. The cell biology of leukocyte-mediated proteolysis.
J Leukoc Biol. 1999;65:14.
40. Maximova K, Venken T, Reuter N, Trylska J. D-peptides as inhibitors of PR3-
membrane interactions. Biomembranes. 1860;2018:458–66.
41. Korkmaz B, Poutrain P, Hazouard E, de Monte M, Attucci S, Gauthier FL.
Competition between elastase and related proteases from human
neutrophil for binding to α1-protease inhibitor. Am J Respir Cell Mol
Biol. 2005;32:553–9.
42. Sinden NJ, Stockley RA. Proteinase 3 activity in sputum from subjects with
Alpha-1 anti-trypsin deficiency and COPD. Eur Respir J. 2013;41:1042–50.
43. Kao RC, Wehner NG, Skubitz KM, Gray BH, Hoidal JR. Proteinase 3. A distinct
human Polymorphonuclear leukocyte proteinase that produces emphysema
in hamsters. J Clin Invest. 1988;82:1963–73.
44. Borel F, Sun H, Zieger M, Cox A, Cardozo B, Li W, Oliveira G, Davis A,
Gruntman A, Flotte TR, et al. Editing out five Serpina1 paralogs to create a
mouse model of genetic emphysema. Proc Natl Acad Sci U S A. 2018;
115(11):2788-93.
45. Lombard C, Bouchu D, Wallach J, Saulnier J. Proteinase 3 hydrolysis of
peptides derived from human elastin exon 24. Amino Acids. 2005;28:403–8.
46. Chelladurai P, Seeger W, Pullamsetti SS. Matrix metalloproteinases and their
inhibitors in pulmonary hypertension. Eur Respir J. 2012;40:766–82.
47. Sand JMB, Knox AJ, Lange P, Sun S, Kristensen JH, Leeming DJ, Karsdal MA,
Bolton CE, Johnson SR. Accelerated extracellular matrix turnover during
exacerbations of COPD. Respir Res. 2015;16:69.
48. Ramaha A, Patston PA. Release and degradation of angiotensin 1 and
angiotensin 2 from angiotensinogen by neutrophil serine proteinases. Arch
Biochem Biophys. 2002;397:77–83.
49. Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, Nusbaum P, Ueki I,
Canteloup S, Lenoir G, Descamps-Latscha B, Nadel JA. Proteinase 3, a potent
Secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir
Cell Mol Biol. 1999;20:729–36.
Crisford et al. Respiratory Research  (2018) 19:180 Page 8 of 10
50. Janciauskiene S, Bals R, Koczulla R, Vogelmeier C, Kohnlein T, Welte T. The
discovery of Alpha-1-antitrypsin and its role in health and disease. Respir
Med. 2011;105:1129–39.
51. Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS,
Borregaard N. Human cathelicidin, hCAP-18, is processed to the
antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3.
Blood J. 2001;97:3951–9.
52. Ren K, Torres R. Role of interleukin-1beta during pain and inflammation.
Brain Res Rev. 2009;60:57–64.
53. Popa C, Netea MG, van Riel PLCM, van der Meer JWM, Stalenhoef AFH. The
role of TNF-a in chronic inflammatory conditions, intermediary metabolism,
and cardiovascular risk. J Lipid Res. 2007;48:751–62.
54. Coeshott C, Ohnemus C, Pilyavskaya A, Ross S, Wieczorek M, Kroona H,
Leimer AH, Cheronis J. Converting enzyme-independent release of tumor
necrosis factor alpha and IL-1beta from a stimulated human Monocytic cell
line in the presence of activated neutrophils or purified proteinase 3. Proc
Natl Acad Sci U S A. 1999;96:6261–6.
55. Keyel PA. How is inflammation initiated? Individual influences of IL-1, IL-18
and HMGB1. Cytokine. 2014;69:136-45.
56. Schreiber A, Pham CT, Hu Y, Schneider W, Luft FC, Kettritz R. Neutrophil
serine proteases promote IL-1beta generation and injury in necrotizing
crescentic glomerulonephritis. J Am Soc Nephrol. 2012;23:470–82.
57. Sugawara A, Uehara A, Nochi T, Yamaguchi T, Ueda H, Sugiyama A,
Hanzawa K, Kumagai K, Okamura H, Takada H. Neutrophil proteinase 3-
mediated induction of bioactive IL-18 secretion by human Oral epithelial
cells. J Immunol. 2001;167:6568–75.
58. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149–60.
59. Hurst SM, Wilkinson TS, McLoughline RM, Jones S, Horiuchi S, Yamamoto N,
Rose-john S, Fuller GM, Topley N, Jones SA. IL-6 and its soluble receptor
Ochestrate a Temportal switch in the pattern of leukocyte recruitment seen
during acute inflammation. Immunity. 2001;14:705–14.
60. McLoughlin RM, Hurst SM, Nowell MA, Harris DA, Horiuchi S, Morgan LW,
Wilkinson TS, Yamamoto N, Topley N, Jones SA. Differential regulation of
neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J
Immunol. 2004;172:5676–83.
61. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in Interleukin-8
and tumour necrosis factor-alpha in induced sputum from patients with
chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care
Med. 1996;153:512–21.
62. Rani L, Minz RW, Sharma A, Anand S, Gupta D, Panda NK, Sakhuja VK.
Predominance of PR3 specific immune response and skewed Th17 vs.
T-regulatory Miliew in active Granfulomatosis with Polyangiitis. Cytokine.
2015;71:7.
63. Kim S-H, Han S-Y, Azam T, Yoon D-Y, Dinarello CA. Interleukin-32: a cytokine
and inducer of TNFα. Immunity. 2005;22:131–42.
64. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, Turato G,
Lokar-Oliani K, Papi A, Zuin R, Sfriso P. IL-32, a novel Proinflammatory
cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care
Med. 2008;178:894–901.
65. Zhang J-M, An J. Cytokines, inflammation and pain. Int Anesthesiol Clin.
2007;45:27–37.
66. Nemeth T, Mocsai A. Feedback amplification of neutrophil function. Cell.
2016;37:412–24.
67. Robache-Gallea S, Morand V, Bruneau JM, Schoot B, Tagat E, Realo E,
Chouaib S, Roman-Roman S. In vitro processing of human tumour necrosis
factor-alpha. J Biol Chem. 1995;270:23688–92.
68. Kessenbrock K, Dau T, Jenne DE. Tailor-made inflammation: how neutrophil
serine proteases modulate the inflammatory response. J Mol Med. 2011;89:23–8.
69. Ungers MJ, Sinden NJ, Stockley RA. Progranulin is a substrate for neutrophil-
elastase and Proteinase-3 in the airway and its concentration correlates with
mediators of airway inflammation in COPD. Am J Physiol Lung Cell Mol
Physiol. 2014;306:L80–7.
70. Couto MA, Harwig SSL, Cullor JS, Hughes JP, Lehrer RI. eNAP-2, a novel
cysteine-rich bactericidal peptide from equine leukocytes. Infect Immun.
1992;60:5042–7.
71. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm
C, Snowden J, Adamson J, Sadovnivk AD, Rollinson S, et al. Mutations in
Progranulin cause tau-negative frontotemporal dementia linked to
chromosome 17. Nature. 2006;442:916–9.
72. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L,
Erdujument-Bromage H, Tempst P, Wright CD, Ding A. Conversion of
Proepithelin to Epithelins: roles of SLPI and elastase in host defense and
wound repair. Cell. 2002;111:867–78.
73. van der Berg CW, Tambourgi DV, Clark HW, Hoong SJ, Spiller OB, McGreal
EP. Mechanism of neutrophil dysfunction: neutrophil serine proteases cleave
and inactivate the C5a receptor. J Immunol. 2014;192:1787–95.
74. Marc MM, Korosec P, Kosnik M, Kern I, Flezar M, Suskovic S, Sorli J.
Complement factors C3a, C4a, and C5a in chronic obstructive pulmonary
disease and asthma. Am J Respir Cell Mol Biol. 2004;31:216–9.
75. Zhang Y, Jiang Y, Sun C, Wang Q, Yang Z, Pan X, Zhu M, Xiao W. The human
cathelicidin LL-37 enhances airway mucus production in chronic obstructive
pulmonary disease. Biochem Biophys Res Commun. 2014;443:103–9.
76. Campanelli D, Detmers PA, Nathan CF, Gabay JE. Azurocidin and a
homologous serine protease from neutrophils. Differential antimicrobial and
proteolytic properties. J Clin Invest. 1990;85:904–15.
77. Dasaraju PV, Liu C. Infections of the respiratory system. In: Medical
Microbiology. 4th ed. Baron S, editor. Texas: University of Texas Medical
Branch at Galveston; 1996.
78. Kuroda K, Okumura K, Isogai H, Isogai E. The human cathelicidin
antimicrobial peptide LL-37 and mimics are potential anti-Cancer drugs.
Front Oncol. 2015;5:10.
79. Jiang Y-Y, Xiao W, Zhu M-X, Yang Z-H, Pan X-J, Zhang Y, Sun C-C, Xing Y.
The effect of human antibacterial peptide LL-37 in the pathogenesis of
chronic obstructive pulmonary disease. Respir Med. 2012;106:1680–9.
80. Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W,
Brinkmann V, Jungblut PR, Sycglinsky A. Neutrophil extracellular traps
contain calprotectin, a cytosolic protein complex involved in host defense
against Candida albicans. PLoS Pathog. 2009;5:e1000639.
81. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z,
Grone H-J, Brinkmann V, Jenne DE. Netting Neutrophils in Autoimmune
Small-Vessel Vasculitis. Nat Med. 2009;15:623–5.
82. Delgado-Rizo V, Martinez-Guzman MA, Iniguez-Gutierrez L, Garcia-Orozco A,
Alvarado-Navarro A, Fafutis-Morris M. Neutrophil extracellular traps and its
implications in inflammation: an overview. Front Immunol. 2017;2017:1–20.
83. Beiter K, Wartha F, Albiger B, Normark S, Zychlinsky A, Henriques-Normark B.
An endonuclease allows Streptococcus pneumoniae to escape from
neutrophil extracellular traps. Curr Biol. 2006;16:401–7.
84. Hong W, Juneau RA, Pang B, Swords WE. Survival of bacterial biofilms
within neutrophil extracellular traps promotes Nontypeable Haemophilus
influenzae persistence in the Chinchilla model for otitis media. J Innate
Immun. 2009;1:215–24.
85. Benarafa C, Priebe GP, Remold-O'Donnell E. The neutrophil serine protease
inhibitor SerpinB1 preserves lung Defence functions in Pseudomonas
aeruginosa infection. J Exp Med. 2007;204:1901–9.
86. Rao NV, Marshall BC, Gray BH, Hoidal JR. Interaction of secretory
leukocyte protease inhibitor with Proteinase-3. Am J Respir Cell Mol Biol.
1993;8:612-6.
87. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial
cell death and decreased expression of vascular endothelial growth factor
and vascular endothelial growth factor receptor 2 in emphysema. Am J
Respir Crit Care Med. 2001;163:737–44.
88. Kolonin AG, Sergeeva A, Staquicini DI, Smith TL, Tarleton CA, Molldrem JJ,
Sidman RL, Marchio S, Pasqualini R, Arap W. Interaction between tumour
cell surface receptor RAGE and proteinase 3 mediates prostate Cancer
Matastasis to bone. Cancer Res. 2017;77:3144–50.
89. Sukkar MB, Ullah MA, Gan WJ, Wark PAB, Chung KF, Hughes JM, Armour CL,
Phipps S. RAGE: a new frontier in chronic airways disease. Br J Pharmacol.
2012;167:1161–76.
90. Yonchuk JG, Silverman EK, Bowler RP, Agusti A, Lomas DA, Miller BE,
Tal-Singer R, Mayer RJ. Circulating soluble receptor for advanced
glycation end products (sRAGE) as a biomarker of emphysema and the
RAGE Axis in the lung. Am J Respir Crit Care Med. 2015;192:785–92.
91. Stehlik C. Multiple IL-1β converting enzymes contribute to inflammatory
arthritis. Arthritis Rheum. 2009;60:3524–30.
92. Lee T-H, Song HJ, Park C-S. Role of Inflammasome activation in development
and exacerbation of asthma. Asia Pacific Allergy. 2014;4:187–96.
93. Toonen EJ, Mirea AM, Tack CJ, Stienstra R, Ballak DB, van Diepen JA, Hijmans
A, Chavakis T, Dokter WH, Pham CT, et al. Activation of proteinase 3
contributes to non-alcoholic fatty liver disease (NAFLD) and insulin
resistance. Mol Med. 2016;22:202–14.
94. Gracie JA. Interleukin-18 as a potential target in inflammatory arthritis. Clin
Exp Immunol. 2004;136:402–4.
Crisford et al. Respiratory Research  (2018) 19:180 Page 9 of 10
95. Matsumoto T, Kaneko T, Seto M, Wada H, Kobayashi T, Nakatani K,
Tonomura H, Tono Y, Ohyabu M, Nobori T, et al. The membrane proteinase
3 expression on neutrophils was downregulated after treatment with
infliximab in patients with rheumatoid arthritis. Clin Appl Thromb Hemost.
2008;14:186-92.
96. Armstrong L, Godinho SIH, Uppington KM, Whittington HA, Millar AB.
Tumour necrosis factor-α processing in interstitial lung disease: a potential
role for exogenous Proteinase-3. Clin Exp Immunol. 2009;156:336–43.
97. McGreal EP, Davies PL, Powell W, Rose-John S, Spiller OB, Doull I, Jones SA,
Kotecha S. Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived
serine proteases in cystic fibrosis. Biochim Biophys Acta. 2010;1802:649–58.
98. Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease.
Ann Rheum Dis. 2006;65:4.
99. Zhao Y-P, Tian Q-Y, Liu C-J. Progranulin deficiency exaggerates, whereas
Progranulin-derived Atsttrin attenuates, severity of dermatitis in mice. FEBS
Lett. 2013;587:6.
100. Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, Syed NM, Lai Y, Lin EA,
Kong L, et al. The growth factor Progranulin binds to TNF receptors and is
therapeutic against inflammatory arthritis in mice. Science. 2011;332:7.
101. Guo Z, Li Q, Han Y, Liang Y, Xu Z, Ren T. Prevention of LPS-induced acute
lung injury in mice by Progranulin. Mediat Inflamm. 2012;2012:10.
102. Goedert M, Spillantini MG. Frontotemporal lobar degeneration through loss
of Progranulin function. Brain Res Rev. 2006;129:2808–10.
103. Bossu P, Salani F, Alberici A, Archetti S, Bellelli G, Galimberti D, Scarpini E,
Spalletta G, Caltagirone C, Padovani A, Borroni B. Loss of function mutations
in the Progranulin gene are related to pro-inflammatory cytokine
dysregulation in frontotemporal lobar degeneration patients. J
Neuroinflammation. 2011;8:65–9.
104. Cruts M, van Broeckhoven C. Loss of Progranulin function in frontotemporal
lobar degeneration. Trends Genet. 2008;24:186–94.
105. Chow MJ, Choi M, Yun SH, Zhang Y. The effect of static stretch on elastin
degradation in arteries. PLoS One. 2013;8:e81951.
106. Kuckleburg CJ, Tilkens SM, Santoso S, Newman PJ. Proteinase 3 contributes
to Transendothelial migration of NB1-positive neutrophils. J Immunol. 2012;
188:2419–26.
107. Wiedow O, Meyer-Hoffert U. Neutrophil serine proteases: potential key
regulators of cell Signalling during inflammation. J Intern Med. 2005;257:319–28.
108. Saragih H, Zilian E, Jaimes Y, Paine A, Figueiredo C, Eiz-Vesper B, Blascysk R,
Larmann J, Theilmeier G, Burg-Roderfeld M, et al. PECAM-1-dependent
Heme Oxygenase-1 regulation via an Nrf2-mediated pathway in endothelial
cells. Thromb Haemost. 2014;111:1077–88.
109. Lutz PG, Houzel-Charavel A, Moog-Lutz C, Cayre YE. Myeloblastin is an Myb
target gene: mechanisms of Regulationin myeloid leukemia cells growth-
arrested by retinoic acid. Blood Journal. 2001;97:2449–56.
110. Lutz PG, Moog-Lutz C, Coumau-Gatbois E, Kobari L, di Gioia Y, Cayre YE.
Myeloblastin is a granulocyte Colony-stimulating factor-responsive gene
conferring factor-independent growth to Haematopoietic cells. Proc Natl
Acad Sci U S A. 2000;97:1601–6.
111. Bories D, Raynal M-C, Solomon DH, Darzynkiewicz Z, Cayre YE. Down-
regulation of a serine protease, Myeloblastin, causes growth arrest and
differentiation of Promyelocytic leukemia cells. Cell. 1989;59:959–68.
112. Martin KR, Kantarl-Mimoun C, Yin M, Perderzoll-Ribell M, Angelot-Delettre F,
Cerol A, Grauffel C, Benhamou M, Reuter N, Saas P, et al. Proteinase 3 is a
phosphatidylserine-binding protein that affects the production and function
of microvesicles. J Biol Chem. 2016;291:10476–89.
113. Cerezo LA, Kuklova M, Hulejova H, Vernerova Z, Kasprikova N, Veigl D,
Pavelka K, Vencovsky J, Senolt L. Progranulin is associate with disease
activity in patients with Rheumatiod arthritis. Mediat Inflamm. 2015;2015:6.
114. Jennette JC, Nachman PH. ANCA glomerulonephritis and Vasculitis. Clin J
Am Soc Nephrol. 2017;12:1680–91.
115. Hozumi H, Enomoto N, Oyama Y, Kono M, Fujisawa T, Inui N, Nakamura
Y, Suda T. Clinical implication of Proteinase-3-Antineutrophil cytoplasmic
antibody in patients with idiopathic interstitial pneumonias. Lung. 2016;
194:235–42.
116. Seo P, Stone JH. The Antineutrophilic cytoplasmic antibody-associated
Vasulitides. Am J Med. 2004;117:39–50.
117. Falk RJ, Jennette JC. Wegener's granulomatosis systemic Vasculitis, and
Antineutrophil cytoplasmic autoantibodies. Annu Rev Med. 1991;42:459–69.
118. Savage COS. Pathogenesis of anti-neutrophil cytoplasmic autoantibody
(ANCA)-associated Vasculitis. Clin Exp Immunol. 2011;164:23–6.
119. Bonarius HPJ, Brandsma CA, Kerstjens HAM, Koerts JA, Kerkhof M,
Nizankowska-Mogilnicka E, Roozendaal C, Postma DS, Timens W. Antinuclear
autoantibodies are more prevalent in COPD in association with low body
mass index but not with smoking history. Thorax. 2011;66:101–7.
120. Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ, Hagen EC, Jayne D,
Jennette JC, Paspaliaris B, et al. International consensus statement on
testing and reporting of Antineutrophil cytoplasmic antibodies (ANCA). Am
J Clin Pathol. 1999;111:507–13.
121. Savige J, Dimech W, Fritzler M, Goeken J, Hagen EC, Jennette JC, McEvoy R,
Pusey C, Pollock W, Trevisin M, et al. Addendum to the international
consensus statement on testing and reporting of Antineutrophil
cytoplasmic antibodies. Am J Clin Pathol. 2003;120:312–8.
122. Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT,
Weiss SL, Fitzgerald J, Checchia PA, Meyer K, et al. A multibiomarker-
based model for estimating the risk of septic acute kidney injury. Crit
Care Med. 2015;43:1646–53.
123. Ng LL, Khan SQ, Narayan H, Quinn P, Squire IB, Davies JE. Proteinase 3 and
prognosis of patients with acute myocardial infarction. Clin Sci. 2011;120:231–8.
124. Carter RI, Ungers MJ, Mumford RA, Stockley RA. Aa-Val360: a marker of
Neurophil elastase and COPD disease activity. Eur Respir J. 2013;41(1):31-8.
Crisford et al. Respiratory Research  (2018) 19:180 Page 10 of 10
